Article
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.
Blood - 28 May 2015
Martelli Maria Paola, Gionfriddo Ilaria, Mezzasoma Federica, Milano Francesca, Pierangeli Sara, Mulas Floriana, Pacini Roberta, Tabarrini Alessia, Pettirossi Valentina, Rossi Roberta, Vetro Calogero, Brunetti Lorenzo, Sportoletti Paolo, Tiacci Enrico, Di Raimondo Francesco, Falini Brunangelo
Abstract excerpt
Nucleophosmin (NPM1) mutations represent an attractive therapeutic target in acute myeloid leukemia (AML) because they are common (∼30% AML), stable, and behave as a founder genetic lesion. Oncoprotein targeting can be a successful strategy to treat AML, as proved in acute promyelocytic leukemia by treatment with all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO), which degrade the promyelocytic leukemia...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.